Circa Scientific, Inc.
$54.8K 11 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
exocad America, Inc.
exocad America, Inc. reported $54,867.50 across General Payments, Research, and Ownership to 13 physicians and teaching hospitals across 13 transactions.
- $54.9K Below-median payer
- All-tracks total
- 13 Below-median volume
- Transactions
- 13 Below-median reach
- Recipients
- +$31.4K
- General Payments vs PY2023
exocad America, Inc. reported $54,867.50 across all CMS Open Payments tracks (General + Research + Ownership) to 13 physicians and teaching hospitals in Program Year 2024 - ranking #1328 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $54,867.50, averaging $4.2K per recipient.
exocad America, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer exocad-america-inc exocad America, Inc.
$54.9K · #1328/1,925 · 0.0% industry · PY2024
- TOT $54.9K
- RANK #1328
- SHARE 0.0%
- TXN 13
- RCP 13
- CAT 3
- GEN $54.9K
- ΔGEN +$31.4K
- TOP1 19.7%
- PY 2024
Volume peers
Nearest volume peer: Circa Scientific, Inc. ($54.8K)
exocad America, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
exocad America, Inc.'s CMS-reported General Payments increased by $31.4K (+133.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EXOCAD AMERICA, INC.PY2023: EXOCAD AMERICA, INC.PY2024: exocad America, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $23,502.57
- PY2024
- $54,867.50
What the Data Shows for exocad America, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For exocad America, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Long-Term Medical Supply or Device Loan" at $49.8K, accounting for 90.8% of this company's General Payments and 9 transactions.
General Payment Breakdown by Type
"Long-Term Medical Supply or Device Loan" leads exocad America, Inc.'s 3-category general-payment breakdown at $49.8K, 90.8% of the reported total.
How exocad America, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Long-Term Medical Supply or Device Loan | $49.8K | 9 | 90.8% |
| Honoraria | $4.9K | 1 | 8.9% |
| Consulting Fee | $179.93 | 3 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $49,800.00 (90.8%) of $54,867.50 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for exocad America, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jeffrey W Horowitz
$10,820.00 across 2 reported transactions
- 2
Jeffrey Zaffos
$10,820.00 across 2 reported transactions
- 3
Isaac David Tawil
$10,820.00 across 2 reported transactions
- 4
Daniel Gary Butterman
$10,820.00 across 2 reported transactions
- 5
Michael David Scherer
$6,520.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
exocad America, Inc. ranks #1328 of 1,925 by total payments (bottom 31% by spend) but is notably more concentrated than that alone would suggest -- #794 of 1,838 by HHI (top 43% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- NS Pharma, Inc. : $103.1K total payments, HHI 1796
- Avid Radiopharmaceuticals, Inc. : $8.1K total payments, HHI 1793
- Applied Medical Technology Inc : $176.9K total payments, HHI 1791
- Ignite Orthopedics, LLC : $705.4K total payments, HHI 1790
- BioPro, Inc. : $101.9K total payments, HHI 1788
- Lazarus 3D : $1.2K total payments, HHI 1788
- exocad America, Inc. (this company) : $54.9K total payments, HHI 1781
- Citieffe, Inc. : $145.4K total payments, HHI 1775
- Diagnostica Stago, Inc : $49.4K total payments, HHI 1775
- Cerus Corporation : $405.7K total payments, HHI 1771
- Brixton Biosciences, Inc. : $36.4K total payments, HHI 1756
- Sysmex America, Inc. : $54.4K total payments, HHI 1755
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as exocad America, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about exocad America, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with exocad America, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Nuvascular Inc.
$55.0K 0 recipients
Compare payment profiles
Eisai Co., Ltd.
$54.3K 17 recipients
Compare payment profiles
Fidia Pharma USA Inc.
$55.5K 2,274 recipients
Compare payment profiles
Integer Holdings Corporation
$54.0K 36 recipients
Compare payment profiles
ICU Medical Inc
$55.8K 117 recipients
Compare payment profiles
Put this to use
exocad America, Inc. ranks #1328 of 1,925 by all-tracks total payments, led by "Long-Term Medical Supply or Device Loan".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Long-Term Medical Supply or Device Loan" spend across every manufacturer, not just exocad America, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.